Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123176322 | 12317632 | 2 | F | 20131112 | 20150601 | 20160429 | 20160728 | PER | US-MYLANLABS-2015M1018555 | MYLAN | 15.09 | YR | M | Y | 74.38000 | KG | 20160728 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123176322 | 12317632 | 1 | PS | DOXYCYCLINE. | DOXYCYCLINE | 1 | Oral | 100 MG, QD | 10500 | MG | Y | 62337 | 100 | MG | TABLET | QD | |||
| 123176322 | 12317632 | 2 | C | ACANYA | BENZOYL PEROXIDECLINDAMYCIN PHOSPHATE | 1 | Topical | APPLICATION TO AFFECTED AREA, HS | 0 | GEL | QD | ||||||||
| 123176322 | 12317632 | 3 | C | TAZORAC | TAZAROTENE | 1 | Topical | APPLICATION TO AFFECTED AREA, AM | 0 | GEL | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123176322 | 12317632 | 1 | Acne |
| 123176322 | 12317632 | 2 | Acne |
| 123176322 | 12317632 | 3 | Acne |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123176322 | 12317632 | Drug ineffective |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 123176322 | 12317632 | 1 | 20130731 | 20131112 | 0 |